B2M and cancer: Among 4 B2M-mutant cancer patients receiving ICB, only one patient (25% as opposed to 46.6% among B2M-wild type cancer patients, p>0.99), with initial disease stabilization, showed PR on subsequent imaging as best response, the other three patients had SD.